<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471223</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-089</org_study_id>
    <nct_id>NCT01471223</nct_id>
  </id_info>
  <brief_title>Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study</brief_title>
  <acronym>CTS</acronym>
  <official_title>Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to estimate the incidence rates of Post-transplant
      Lymphoproliferative Disorder (PTLD), malignancy and hospitalized infections in adult
      kidney-only transplant recipients treated with Belatacept, and compared the incidences to the
      incidences in those treated with Calcineurin inhibitor (CNI) based regimens at the time of
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Time Perspective: Prospective design, Retrospective data collection and analysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2012</start_date>
  <completion_date type="Actual">August 8, 2017</completion_date>
  <primary_completion_date type="Actual">August 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of Post-transplant Lymphoproliferative Disorder (PTLD)</measure>
    <time_frame>5 years post transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidences of hospitalized infections</measure>
    <time_frame>2 years post transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidences of malignancy</measure>
    <time_frame>5 years post transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of PTLD in adult subgroups of Belatacept- vs. CNI-treated, kidney-only transplant recipients defined by donor-recipient Epstein Barr virus (EBV) serostatus and by age groups</measure>
    <time_frame>Every 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location, mortality, and tumor type of all PTLD cases in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation and in subgroups of these transplant recipients</measure>
    <time_frame>Every 6 months and 12 months</time_frame>
    <description>Subgroups of the transplant recipients defined by donor-recipient EBV serostatus at the time of transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of hospitalized infections in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation</measure>
    <time_frame>Every 6 months and 12 months</time_frame>
    <description>Hospitalized infections for the following infection groups:
Bacterial
fungal
Viral
Tuberculosis
Herpes and
Cytomegalovirus (CMV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of graft rejection in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation</measure>
    <time_frame>Every 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of graft failure in adult kidney-only transplant recipients treated with Belatacept vs. CNI-based regimens at the time of transplantation</measure>
    <time_frame>Every 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate of composite bacterial, fungal, viral, tuberculosis, herpes, and CMV infections</measure>
    <time_frame>2 years post transplantation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Patients receiving Belatacept in CTS</arm_group_label>
    <description>Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving CNI in CTS</arm_group_label>
    <description>Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing 1st kidney only transplantation, whose transplant centers participate
        in CTS and who are treated with Belatacept or a CNI based regimen at the time of
        transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st kidney only transplant during study, at one of the transplant centers
             participating in CTS, received Belatacept or a CNI at the time of transplantation

        Exclusion Criteria:

          -  Patients with a history of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

